Ireland
--:--IST
Clinical Trials in the EU / 2026-525935-18-01
Authorised, not yet recruiting Phase II

Endocrinological Support Therapy After Military Operations

2026-525935-18-01 · tracked via the Priya Life Science EU tracker
Sponsor
Norges Idrettshoegskole
Sponsor type
Educational Institution
Therapeutic area
Musculoskeletal and Neural Physiological Phenomena
Decision date
08/10/2026
Enrollment target
22
Sites
Norway

Condition studied

The participants do not have any medical condition

Investigational medicinal product(s)

Natriumklorid Fresenius Kabi 9 mg/ml infusjonsvæskeoppløsningNebido 1000 mg/4 ml injeksjonsvæske

Every trial of Testosterone Undecanoate across our registers →

Eligibility

Age group
18-64 years
Sex
Male

Primary endpoint

Recovery of countermovement jump height measured using countermovement jumps performed on a force plate., Recovery of lower-body explosive performance, assessed as peak power and peak velocity during the Keiser leg-press test throw distance in the medicine ball throw., Recovery of maximal muscle strength, assessed as peak force during the Keiser leg-press test and maximal grip strength, Recovery of local muscular endurance as number of repetitions on the pull up test., Recovery of anaerobic performance measured as peak and mean power in the Wingate test.

Endpoint detail

Recovery of body mass, fat mass, lean body mass as measured with Inbody, Recovery of reaction time as measured by the stroop test and mental flexibility, visual attention and processing speed as measured by the trail making test, Recovery in perceived recovery measured with the perceived recovery status, Recovery in serum cortisol, serum testosterone and serum IGF-1.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525935-18-01 on CTIS ↗ ← All trials in the EU